Pregnancy Clinical Trial
Official title:
Preterm Birth in Nulliparous Women: An Understudied Population at Great Risk
Forty percent of pregnant women in the United States are women who have never given birth. As a group, they sometimes have complications with their pregnancy, but there is no information from a previous pregnancy to identify who might have a problem. Very little research has been done with this group. The Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (nuMoM2b) is collecting data from a diverse population of about 10,000 women who are having their first baby and are carrying only one baby. The women are enrolled early in pregnancy and undergo research assessments four times during their pregnancies. Data are collected through interviews, self-completed data forms, clinical measurements, ultrasound, and collection and storage of blood samples, urine samples, and fluid from the vagina and cervix. Some information comes from medical records. A subset of women may be asked to participate in substudies collecting information on sleep breathing, sleep patterns and quality, or other areas possibly related to birth outcomes. The goal of the research is to find ways to identify women in this group who might develop a problem with their pregnancy and use this information to improve the health of pregnant women and their babies in the future. The study is focusing on pregnancy problems like high blood pressure, babies that are born much too early and very small babies.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
established the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (nuMoM2b) to
study women for whom the current pregnancy will lead to their first delivery (nulliparas).
About 40% of pregnant women in the United States are nulliparas. Because little or no
information from previous pregnancy outcomes is available to guide assignment of risk or
mitigating interventions, adverse pregnancy outcomes in nulliparas are especially
unpredictable. The underlying mechanisms of adverse pregnancy outcomes such as preterm
birth, preeclampsia, fetal growth restriction and stillbirth are interrelated and therefore
will be evaluated as part of this study. The information gained will benefit women who are
pregnant or who are considering pregnancy and their physicians. In addition, the knowledge
will support future research aimed at improving care and health outcomes for a critical
group of at-risk women who are currently understudied.
The study is a prospective cohort study of a racially/ethnically/geographically diverse
population of 10,038 nulliparous women with singleton gestations. The women undergo
intensive research assessments during the course of their pregnancies to study the
mechanisms for and prediction of adverse pregnancy outcomes (APOs) in women in their first
pregnancy. The APOs of primary interest are preterm birth, preeclampsia and fetal growth
restriction.
The goals of the study are to 1) determine maternal characteristics, including genetics,
epigenetics, and physiological response to pregnancy as well as environmental factors that
influence and/or predict adverse pregnancy outcome; 2) identify specific aspects of
placental development and function that lead to adverse pregnancy outcome; and 3)
characterize genetic, growth, and developmental parameters of the fetus that are associated
with adverse pregnancy outcome.
Eight academic medical centers or sites had primary responsibility for enrollment and
follow-up of study participants. Several of these sites collected data through additional
academic research centers or nearby hospitals (subsites). A Data Coordinating and Analysis
Center (DCAC) provided input to the protocol, manages the data, and analyzes the data.
Investigators from these institutions have established a partnership with NICHD staff to
develop and implement the study protocol and ancillary studies that acquire and analyze data
to identify biomarkers and understand the mechanism and prediction of preterm birth and
other adverse pregnancy outcomes.
Nulliparous women with an in utero singleton gestation between 6 weeks 0 days and 13 weeks 6
days of pregnancy were recruited through the eight clinical sites and their subsites.
Mechanisms were created in the various prenatal clinics associated with the sites to
identify eligible nulliparous women with singleton pregnancies. Once enrolled, a participant
was followed for the duration of her pregnancy by research staff at the clinical site. Study
visits were scheduled at four times during the pregnancy: 6 weeks 0 days through 13 weeks 6
days estimated gestational age (EGA), 16 weeks 0 days through 21 weeks 6 days EGA, 22 weeks
0 days through 29 weeks 6 days EGA, and at the time of delivery. Data were collected through
personal interview, self-administered questionnaires, clinical measurement, chart
abstraction, and collection of biological specimens (blood, urine, cervico-vaginal fluid).
Additional data (i.e., sleep breathing assessments, actigraphy, fetal adrenal gland
measurements) were collected through ancillary research studies on subsets of the enrolled
women. The set-ups for screening, enrollment and follow-up of participants varied by
clinical site and subsite. However, in each setting, the clinical site staffs included study
investigators, research nurses, research assistants and sonographers. Clinical site staffs
were trained to interview participants, collect and process samples, conduct various
research tests, and input data. Data are managed at the DCAC. Specimens are stored at the
NICHD specimen repository for later analysis.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Completed |
NCT02408315 -
Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)
|
Phase 3 |